Vieworks Co., Ltd. (KOSDAQ:100120)
20,150
-50 (-0.25%)
Sep 5, 2025, 3:30 PM KST
Vieworks Revenue
Vieworks had revenue of 62.70B KRW in the quarter ending June 30, 2025, with 15.64% growth. This brings the company's revenue in the last twelve months to 225.23B, down -1.60% year-over-year. In the year 2024, Vieworks had annual revenue of 222.90B with 1.20% growth.
Revenue (ttm)
225.23B
Revenue Growth
-1.60%
P/S Ratio
0.80
Revenue / Employee
462.48M
Employees
487
Market Cap
181.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 222.90B | 2.65B | 1.20% |
Dec 31, 2023 | 220.25B | -17.68B | -7.43% |
Dec 31, 2022 | 237.93B | 44.79B | 23.19% |
Dec 31, 2021 | 193.14B | 32.88B | 20.51% |
Dec 31, 2020 | 160.26B | 24.25B | 17.83% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
LigaChem Biosciences | 148.28B |